Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
COSCIENS Biopharma ( (TSE:CSCI) ) just unveiled an update.
COSCIENS Biopharma Inc. reported to U.S. and Canadian regulators that it has called a virtual special meeting of security holders, setting March 3, 2026 as the record date for notice, voting and beneficial ownership determination, with the meeting scheduled for April 7, 2026. The filing, dated February 13, 2026, emphasizes extensive forward-looking risks tied to its natural-ingredient extraction, nutraceutical pipeline, Macrilen commercialization, facility build-outs and capital resources, underscoring the company’s cautious stance on future performance and its ongoing strategic shift, including the sunsetting of several R&D programs.
More about COSCIENS Biopharma
COSCIENS Biopharma Inc. is a biopharmaceutical company focused on patented technologies, value-driving products and active ingredients extracted from natural sources for nutraceutical and therapeutic applications. Its pipeline includes oat-based products such as oat beta-glucan, avenanthramides and yeast-derived beta-glucan, as well as the growth hormone diagnostic drug Macrilen (macimorelin), and it is scaling its PGX Technology and facilities in Edmonton and at the Natex Termitz site.
Average Trading Volume: 2,669
Technical Sentiment Signal: Sell
Current Market Cap: C$8.72M
Find detailed analytics on CSCI stock on TipRanks’ Stock Analysis page.